Dechra Pharmaceuticals PLC

DB:1PK0 Stock Report

Market Cap: €5.1b

Dechra Pharmaceuticals Management

Management criteria checks 4/4

Dechra Pharmaceuticals' CEO is Ian Page, appointed in Nov 2001, has a tenure of 22.17 years. total yearly compensation is £1.04M, comprised of 59.9% salary and 40.1% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth €18.16M. The average tenure of the management team and the board of directors is 4.8 years and 4.3 years respectively.

Key information

Ian Page

Chief executive officer

UK£1.0m

Total compensation

CEO salary percentage59.9%
CEO tenure22.2yrs
CEO ownership0.4%
Management average tenure4.8yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ian Page's remuneration changed compared to Dechra Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023UK£1mUK£621k

-UK£28m

Mar 31 2023n/an/a

UK£6m

Dec 31 2022n/an/a

UK£40m

Sep 30 2022n/an/a

UK£49m

Jun 30 2022UK£2mUK£597k

UK£58m

Mar 31 2022n/an/a

UK£66m

Dec 31 2021n/an/a

UK£73m

Sep 30 2021n/an/a

UK£64m

Jun 30 2021UK£3mUK£551k

UK£56m

Mar 31 2021n/an/a

UK£50m

Dec 31 2020n/an/a

UK£44m

Sep 30 2020n/an/a

UK£39m

Jun 30 2020UK£2mUK£517k

UK£34m

Mar 31 2020n/an/a

UK£31m

Dec 31 2019n/an/a

UK£29m

Sep 30 2019n/an/a

UK£30m

Jun 30 2019UK£3mUK£500k

UK£31m

Mar 31 2019n/an/a

UK£28m

Dec 31 2018n/an/a

UK£25m

Sep 30 2018n/an/a

UK£30m

Jun 30 2018UK£3mUK£500k

UK£36m

Mar 31 2018n/an/a

UK£40m

Dec 31 2017n/an/a

UK£43m

Sep 30 2017n/an/a

UK£35m

Jun 30 2017UK£3mUK£490k

UK£26m

Compensation vs Market: Ian's total compensation ($USD1.31M) is below average for companies of similar size in the German market ($USD2.91M).

Compensation vs Earnings: Ian's compensation has been consistent with company performance over the past year.


CEO

Ian Page (62 yo)

22.2yrs

Tenure

UK£1,037,000

Compensation

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...


Leadership Team

NamePositionTenureCompensationOwnership
Ian Page
CEO, MD & Executive Director22.2yrsUK£1.04m0.36%
€ 18.2m
Paul Sandland
CFO & Executive Director4.8yrsUK£641.00k0.010%
€ 525.6k
Patrick Meeus
Chief Scientific Officer1.5yrsno datano data
Jamie Adams
Chief Information Officer1.6yrsno datano data
Katy Clough
Chief People Officerno datano datano data
Mike Eldred
President of North Americano datano datano data
Melanie Hall
Company Secretary6.5yrsno datano data

4.8yrs

Average Tenure

53yo

Average Age

Experienced Management: 1PK0's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ian Page
CEO, MD & Executive Director26.6yrsUK£1.04m0.36%
€ 18.2m
Paul Sandland
CFO & Executive Director4.3yrsUK£641.00k0.010%
€ 525.6k
Geeta Gopalan
Independent Non-Executive Directorless than a yearUK£36.00kno data
Lawson MacArtney
Senior Independent Director7.1yrsUK£107.00k0.0052%
€ 263.8k
Alison Platt
Independent Non-Executive Chairman3.8yrsUK£207.00k0.0033%
€ 166.7k
Lisa Morrison
Designated Non-Executive Director4.9yrsUK£72.00k0.0012%
€ 61.9k
John Shipsey
Independent Non-Executive Director1.6yrsUK£73.00k0.00053%
€ 27.1k

4.3yrs

Average Tenure

59yo

Average Age

Experienced Board: 1PK0's board of directors are considered experienced (4.3 years average tenure).